Amgen Inc (AMGN) FinancialsAMGNFinancialAmgen Inc

Amgen Inc (AMGN) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Other products, accounting for 16.9% of total sales, equivalent to $1.70B. Other significant revenue streams include Repatha and Prolia. Understanding this composition is critical for investors evaluating how AMGN navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Amgen Inc maintains a gross margin of 72.64%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 35.55%, while the net margin is 23.62%. These profitability ratios, combined with a Return on Equity (ROE) of 91.47%, provide a clear picture of how effectively AMGN converts its operational activities into shareholder value.

In the context of the broader market, AMGN competes directly with industry leaders such as GILD and GMAB. With a market capitalization of $236.25B, it holds a leading position in the sector. When comparing efficiency, AMGN's gross margin of 72.64% stands against GILD's 79.76% and GMAB's 92.73%. Such benchmarking helps identify whether Amgen Inc is trading at a premium or discount relative to its financial performance.

Amgen's total revenue has shown consistent growth, with Q2 2026 revenue reported at $10.05 billion, up from $9.86 billion in Q4 2025. The gross margin is strong at 72.64%, and the net income for Q2 2026 was $2.375 billion, reflecting robust profitability.